Reduced<i>miR-215</i>expression predicts poor prognosis in patients with acute myeloid leukemia

Wang, Yuxin; Zhang, Ting‐Juan; Yang, Dongqin; Yao, Dong‐ming; Yang, Lei; Zhou, Jing‐Dong; Deng, Zhaoqun; Ma, Ji‐chun; Guo, Hong; Wen, Xiang‐mei; Jiang, Lin; Qian, Jun

doi:10.1093/jjco/hyv204

Cited by 27 publications

(22 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been found that miR-215 function as tumor suppressors in multiple cancers including gastric cancer, colon cancer, breast cancer, lung cancer, renal cell carcinoma acute myeloid leukemia, and glioma (32)(33)(34)(35)(36)(37)(38)(39)(40). As one of the P53-inducable miRNAs (23,24), miR-215 takes part in cancer development and progression through targeting YY-1, KDM1B, ZEB2, AKT1, XIAP, and RB1 (32)(33)(34)(35)(36)(37)(38)(39)(40). Interestingly, miR-215 is also a hypoxia-induced miRNA in glioma and vital for reprograming glioma-initiating cells to fit the hypoxic microenvironment via suppressing the expression of an epigenetic regulator KDM1B and modulating activities of multiple pathways.…”

Section: Discussionmentioning

confidence: 99%

The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma

Ren

Shang

et al. 2017

Journal of Biological Chemistry

View full text Add to dashboard Cite

The long non-coding RNA (lncRNA) resides in the chromosome 8q24 cancer-risk locus and acts as a vital oncogene during tumorigenesis and progression. However, how is post-transcriptionally regulated, for example, by small ncRNAs, such as microRNAs (miRNAs) is largely unknown. Here, we report how miRNAs regulate expression and also investigate the biological significance of this regulation in hepatocellular carcinoma (HCC). We found that miR-215, a P53-inducible miRNA, is a key regulator of expression in HCC and identified an interaction between miR-215 and PCAT-1 in dual luciferase reporter gene assays. We also found that post-transcriptional silencing of by miR-215 or siRNAs significantly inhibited proliferation of HCC cells and, conversely, that inhibition of endogenous miR-215 up-regulated PCAT-1 expression and promoted cell viability. The tumor-suppressing role of miR-215 was further confirmed in an mouse HCC xenograft model. Of note, gene profiling assays suggested that the kinase CRK-like proto-oncogene, adaptor protein (CRKL), is a potential downstream target of the miR-215-PCAT-1 axis in HCC, and we demonstrated that CRKL silencing significantly suppresses cell proliferation. Taken together and considering the essential role of CRKL in cancer cells, we propose that the TP53-miR-215-PCAT-1-CRKL axis might represent an important regulatory pathway in HCC. In summary, our results highlight the involvement of several ncRNAs in HCC and thus provide critical insights into the molecular pathways operating in this malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma

Ren

Shang

et al. 2017

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…A number of biomarkers are currently used for the diagnosis, prognosis evaluation and treatment strategy of patients with AML, including karyotype, molecular classifications and mutation analysis (2). Classically, specific recurrent chromosomal translocations, including inversion (16) [inv (16)], translocation (8;21) [t(8;21)] and t (15;17) indicate a positive prognosis, while chromosomal deletions (dels) including del(5q), -5 and -7 are associated with more severe disease phenotypes.…”

Section: Introductionmentioning

confidence: 99%

High expression of microRNA‑500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation

et al. 2019

View full text Add to dashboard Cite

MicroRNA-500 (miR-500) is a potential prognostic biomarker in a number of different types of cancer, such as prostate cancer and hepatocellular carcinoma. This study aimed to explore the clinical implications of miR-500 expression status in patients with acute myeloid leukemia (AML) that had received allogeneic hematopoietic stem cell transplantation (allo-HSCT). miR-500 expression status and clinical data were obtained from 74 patients with AML in the The Cancer Genome Atlas database receiving allo-HSCT. Patients with low expression level of miR-500 (miR-500 low) were significantly more likely to present with a French-American-British classification M2 subtype (P=0.003), and less likely to have the M5 subtype (P=0.040) compared with patients with high expression levels (miR-500 high). miR-500 low patients were associated with low-risk AML (P=0.003) and core-binding factor subunit b-myosin heavy chain 11 translocation mutation (P=0.021). There was a significant difference in nucleophosmin 1 (P= 0.009), NRAS proto-oncogene GTPase/KRAS proto-oncogene GTPase (P= 0.047) and PHD finger protein 6 (P= 0.040) expression levels between the two groups. miR-500 high patients had a decreased overall survival (OS) time compared with the low expression group (P=0.035). Multivariate analysis revealed that miR-500 expression significantly affected OS time independent of other classical prognostic factors, such as age and common mutations. The analysis of survival curves further substantiated this result. The results obtained in the current study suggested that miR-500 may be a suitable prognostic marker for patients with AML receiving allo-HSCT.

show abstract

“…A wide range of evidence has indicated that ncRNAs such as circRNAs play an important role in leukemogenesis [19][20][21]; thus, circRNA-based therapy is a feasible approach for the treatment of AML. Aberrant circRNA expression has been associated with the malignant …”

Section: Discussionmentioning

confidence: 99%

Circ-ANAPC7 is Upregulated in Acute Myeloid Leukemia and Appears to Target the MiR-181 Family

Chen

Liu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circular RNAs (circRNAs) are a family of novel non-coding RNAs associated with various diseases, especially cancer. Recent studies have demonstrated that circRNAs participate in pathogenesis mainly by acting as microRNA (miRNA) sponges. The expression profile of circRNAs in acute myeloid leukemia (AML) has rarely been reported. Methods: Profiles of circRNAs were analyzed using an Arraystar human circRNA microarray with 5 bone marrow samples from patients with newly diagnosed AML and 5 from patients with iron-deficiency anemia. Quantitative reverse transcription PCR was used to validate the expression pattern of circRNAs. Furthermore, circRNA–miRNA network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were applied. Results: CircRNA microarray analysis revealed that 698 circRNAs were differentially expressed in AML patients, with 282 circRNAs found to be upregulated and 416 to be downregulated. Quantitative reverse transcription PCR showed that circ-ANAPC7 was significantly upregulated in AML. Bioinformatics analysis predicted that circ-ANAPC7 acts as a sponge for the miR-181 family, KEGG analysis revealed that it is associated with cancer-related pathways, and GO analysis indicated that most of its target genes are involved in biological processes. Conclusions: These findings show that circ-ANAPC7 is a promising biomarker for AML, and that it might participate in AML pathogenesis by acting as a sponge for the miR-181 family.

show abstract

ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia

Cited by 27 publications

References 49 publications

The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma

The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma

High expression of microRNA‑500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation

Circ-ANAPC7 is Upregulated in Acute Myeloid Leukemia and Appears to Target the MiR-181 Family

Contact Info

Product

Resources

About